Dr Martin Edwards
Dr Martin Edwards is the London-based partner of Novo Ventures. He has worked for 22 years in the pharmaceutical and biotechnology industries including 4 years as worldwide head of drug development for Novo Nordisk in Copenhagen and 6 years working in the USA including 4 years as V.P for Pharmacology and Medical Affairs at Zymogenetics. Immediately prior to joining Novo A/S, Dr Edwards was CEO of ReNeuron PLC taking that company public in 2000. He is currently also chairman of Symphogen A/S, a Board member of Serentis Inc and teaches at the Scandinavian International Management Institute.